Literature DB >> 7664482

Clinical and analytical considerations in the utilization of cholinesterase measurements.

M J McQueen1.   

Abstract

Many theories have been advanced but the true physiological function for serum cholinesterase has still not been identified. Evidence has been presented for the abnormal expression of cholinesterase genes in many types of human tumors. Cholinesterase measurements are still used to monitor exposure to organophosphate insecticides and their clinical application requires a good understanding of the inter and intra-individual variation, as well as some knowledge of the time sequence between exposure and measurement of the cholinesterase activity. The use of serum cholinesterase measurement in liver disease varies in different countries. A case has not been made for the cost-effectiveness of adding serum cholinesterase as part of a screening procedure for the diagnosis of liver disease. During the last 10 years much information has been obtained on the molecular biology and genetics of acetylcholinesterase and butyrylcholinesterase, distinct enzymes encoded by two different, but related genes. It has been established that BChE is included by a single gene which corresponds to the E1 locus. The complete amino acid sequence of human serum cholinesterase and the location of disulfide bonds within the sequence have been described. The molecular basis of many variants of human serum cholinesterase has been described in detail. It is not rare for multiple mutations to occur within a single butyrylcholinesterase gene or there may be combination of mutations. At least 11 silent variants of human butyrylcholinesterase have been identified. There still exists a wide variety of substrates and analytical conditions for butyrylcholinesterase measurement in a number of clinical situations. No real evidence has been provided for clinical value for their use in the diagnosis of Alzheimer disease or monitoring the use of cholinesterase inhibitors in the treatment of pre-senile dementia of Alzheimer type. However, the insights from molecular biology technology may well open up more challenges in a variety of clinical situations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7664482     DOI: 10.1016/0009-8981(95)06067-n

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  Potential role of cholinesterases to predict short-term outcome after hepatic resection for hepatocellular carcinoma.

Authors:  Matteo Donadon; Matteo Cimino; Fabio Procopio; Emanuela Morenghi; Marco Montorsi; Guido Torzilli
Journal:  Updates Surg       Date:  2012-08-22

2.  Validation of an automated spectrophotometric assay for the determination of cholinesterase activity in canine serum.

Authors:  T Furlanello; G Simonato; M Caldin; D De Lorenzi; G Lubas; D Bernardini; L Solano-Gallego
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

3.  Black and non-black population: investigation of the difference in butyrylcholinesterase activity in a healthy population in Salvador, Bahia.

Authors:  Jucelino Nery da Conceição Filho; Iris Campos Dos Santos; Davi Pereira de Jesus Gonçalves; Junia Raquel Dutra Ferreira; Ana Leonor Pardo Campos Godoy
Journal:  Ir J Med Sci       Date:  2022-07-06       Impact factor: 1.568

4.  Variation of cholinergic biomarkers in brain regions and blood components of captive mink.

Authors:  Niladri Basu; Anton Scheuhammer; Kirsti Rouvinen-Watt; Nicole Grochowina; Douglas Evans; Hing Man Chan
Journal:  Environ Monit Assess       Date:  2009-03-07       Impact factor: 2.513

5.  Significance of serum butyrylcholinesterase levels in oral cancer.

Authors:  K Prabhu; D Naik; S Ray; A Rao; A Kamath
Journal:  Australas Med J       Date:  2011-07-31

6.  A Comprehensive Study Monitoring the Venom Composition and the Effects of the Venom of the Rare Ethiopian Endemic Snake Species Bitis parviocula.

Authors:  Vladimír Petrilla; Magdaléna Polláková; Barbora Bekešová; Zuzana Andrejčáková; Radoslava Vlčková; Dana Marcinčáková; Monika Petrillová; Eva Petrovová; Drahomíra Sopková; Jaroslav Legáth
Journal:  Toxins (Basel)       Date:  2021-04-22       Impact factor: 4.546

7.  Acetylcholinesterase assay for cerebrospinal fluid using bupivacaine to inhibit butyrylcholinesterase.

Authors:  W H Kluge; H H Kluge; H I Bauer; S Pietsch; J Anders; R A Venbrocks
Journal:  BMC Biochem       Date:  2001-12-21       Impact factor: 4.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.